Perla Colunga

Hematóloga, Profesor Investigadora, Hematologia en @UANL y @FMUANL 🇲🇽 interés en BMT y Linfoma

[Perla Colunga @PerlaRcp]

New publication 📢

Very exciting news about Nivo for HL over the last months, unfortunately its access is still troubling in LATAM. Here we report our center's experience with reduced doses of Nivo in r/r HL
✅73% ORR
✅43% CR

https://t.co/CCD9mdyHjV

[Dr. Luis Villela @hematologo]

Our Real-world paper about plasmablastic lymphoma is out ! Kudos @HumbertoMar_Cor @GELL01433166 @Grupo_GELL . One of the largest series published.

[Héctor A. Vaquera @VaqueraH_md]

Beyond excited to receive @TheEBMT Outreach Travel Grant for the ITCT🥳

Many thanks for all the support to @TheEBMT and my mentors 🙌🏾 @morcossandino @PerlaRcp

See you in Barcelona! 🇪🇸

[Women in Lymphoma - [email protected] @WomenInLymphoma]

Please welcome Astrid Pavlovsky as the incoming co-Chair of @WomenInLymphoma alongside Anna Sureda.
In this video, Astrid shares her vision for the future, the values that drive the community, and what’s coming next.

[Alejandra De Las Fuentes @a_delasfuentes]

Excited to share our systematic review and meta-analysis on early GVHD prophylaxis in haploidentical HSCT and its potential role in reducing CRSA. Early immunosuppression showed promising results, but prospective studies are still needed. Always happy to work with the best team

[Women in Lymphoma - [email protected] @WomenInLymphoma]

🚨 ¡Comienza la Serie 18 en Español de WiL!

🗓 6 mayo 2026
🎓 Diagnóstico en linfomas no Hodgkin: lo clave en la práctica clínica

👩‍⚕️ Dra. Marcela de Dios Soler + Dra. Leticia Quintanillas

🔗 Sumate: #Linfoma #Hematología #WiL

[Women in Lymphoma - [email protected] @WomenInLymphoma]

Coming soon: #WiLingWednesdays Series 18 – LATAM Series
Free educational webinars in Spanish featuring global experts, with a special focus on Latin America
📅 May–June 2026
🌍 Women in Lymphoma: one global community, one shared purpose 💜

[Andres Gomez @GomezDLeonMD]

Transplant is very hard to implement in LMICs.

We have done it through hard work, creativity, clinical research and institutional support.

Fact accredited, now working hard to implement #CARTcells.

The @TheEBMT made a video about our transplant program. Watch it here:
https://t.co/5zqzSO0dTY

[Alan Skarbnik @ASkarbnik]

In the US we argue CAR-T vs bispecifics while 36% of Latin America fights for access to rituximab.

Let that sink in.

GELL Survey 2025 — 73 centers, 16 countries:

73% highly restricted access to bispecifics
~0% commercial CAR-T outside Brazil
Only 15% have NGS
Only 35% access to clinical trials

We’re having 2026 debates with early 2000s access.

The real question isn’t CAR-T vs bispecifics. It’s: how do we close this gap?

Sobering data presented by @DrMCanales here in Chile. @LymphomaEx

Colunga-Pedraza et al. Blood 2025;146(Suppl 1):6193

#Lymphoma #DLBCL #LATAM #GlobalOncology #HealthEquity

[Perla Colunga @PerlaRcp]

@rennquevedo Felicidades !!

[Andres Gomez @GomezDLeonMD]

https://t.co/jgJn9UysZF

[Perla Colunga @PerlaRcp]

@DrRaulCordoba @MDAnderson_ES Felicidades Doctor!! Mucho éxito

[Mostafa Faisal @MostafaFaisal14]

Danazol treatment for poor graft function after hematopoietic stem cell transplantation: a single centre experience @BMTjournal
https://t.co/uFyKvqOJr6

[OncoDaily @oncodaily]

Mentorship and Community at the Women in Lymphoma Meeting - Perla Colunga (@PerlaRcp)

@WomenInLymphoma @DrCarlaCasulo

https://t.co/hwEDb9Ms8W

#OncoDaily #Oncology #Cancer #Health #Medicine

[Perla Colunga @PerlaRcp]

One week ago at #ASH25, the Women in Lymphoma meeting @WomenInLymphoma . Grateful for the opportunity to receive mentorship from @DrCarlaCasulo. Already looking forward to 2026.

[Héctor A. Vaquera @VaqueraH_md]

Important conclusions were drawn from this study:

1. There's a gigantic room for improvement in outcome definition, selection, and implementation in ITP clinical trials

2. Friendship and brightly kind mentorship are a great motor for science

Happy for this incredible humans

[Héctor A. Vaquera @VaqueraH_md]

So privileged to share office, laughs, friendship, ideas, work, advice, worries, victories, and every single up and down with these two incredible women

Thanks for being such an exemplary role model and mentor @PerlaRcp

HBD Ale!! Always better to do science with a great friend

[Héctor A. Vaquera @VaqueraH_md]

Lucky us we got the best @PerlaRcp #ASH25

[Perla Colunga @PerlaRcp]

Couldn’t agree more 👁️

[Andres Gomez @GomezDLeonMD]

Trainees beware🚨Meetings like #ASH25 are high-density environments of social validation and external rewards.

Extrinsic goals provide temporary satisfaction, undermine autonomy and have negative psychological effects!

Instead focus on intrinsic goals like personal growth, relationships, and community contribution, you will be proud and need no applause.

[Perla Colunga @PerlaRcp]

Happy to share our work #ASH25, in collaboration with @GELL_Group!

Lymphoma care has advanced — but access remains unequal.

70+ Latin America centers:
-Limited access to clinical trials
-CAR-T in only 8%
-Novel therapies highly restricted

Closing these gaps must be a priority

[Perla Colunga @PerlaRcp]

@sofiarivarolac @Grupo_GELL Congrats Sofia